Forest Laboratories and Glenmark Pharmaceuticals, a subsidiary of Glenmark Pharmaceuticals India have announced poor results from a dose range-finding study of oglemilast in patients with chronic obstructive pulmonary disease (COPD).

Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo. Oglemilast was, however, well tolerated at all doses studied.

Forest Laboratories chairman and chief executive officer Howard Solomon said that the company was disappointed about the study results but still sees oglemilast as an important and novel therapeutic target for COPD.

“Oglemilast is still being studied for the treatment of asthma, with results expected during the first calendar quarter of 2010. We are considering together with Glenmark what further action would be useful or appropriate,” Solomon said.

The 12-week randomised, double-blind, placebo-controlled, multi-centre Phase IIb study evaluated the efficacy and safety of once-daily oglemilast in patients with moderate to very severe COPD. Patients were at least 40 years of age with a history of heavy smoking.